Shedding fragments of cd44, utilization thereof and inhibition of the shedding

By clarifying the mechanism of the acquisition of cell mobility, it is intended to provide a means of estimating the migration, infiltration, wandering and/or metastasis of cells relating to pathological conditions (for example, cancer cell metastasis, blood cell infiltration) or possibility of the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	MOTOHARU SEIKI, KENICHI OBATA, TOHRU OKU
Format:	Patent
Sprache:	eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PHYSICS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	By clarifying the mechanism of the acquisition of cell mobility, it is intended to provide a means of estimating the migration, infiltration, wandering and/or metastasis of cells relating to pathological conditions (for example, cancer cell metastasis, blood cell infiltration) or possibility of the same and suppressing and/or inhibiting these phenomena involving the pathological conditions. It is found out that shedding of CD44 with MMPs (in particular membrane-attached MMP involving MT1-MMP) triggers morphological and functional changes of cells. Based on this finding, it is possible to provide a means of estimating pathological conditions such as cancer cell metastasis and blood cell infiltration by assaying CD44 fragments formed by the shedding and reagents such as monoclonal antibodies useful therein. Moreover, use of mutant CD44 proteins resistant to the above shedding, MMP inhibitors, anti-MMP antibodies, etc. contributes to the prevention and treatment of disorders, abnormalities and/or diseases in association with the shedding of CD44.